Evidence map›Paper›PMID 24626156›Full record

ReviewCurrent opinion in pediatrics2014

Fluconazole prophylaxis for prevention of invasive candidiasis in infants.

Jessica E Ericson, Daniel K Benjamin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 23 citations in OpenAlex.

  1. Synergistic Inhibition ofPathogens (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Golden hour of neonatal life: Need of the hour.Maternal health, neonatology and perinatology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jessica E EricsonaDuke Clinical Research Institute bDepartment of Pediatrics, Duke University, Durham, North Carolina, USA.
Daniel K Benjamin
Clinical Research Institute · USDuke University · US

Funding

Duke CTSA (Composite)UL1TR001117 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, LI, JENNIFER S · 2013 to 2017
$41.3M
Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental OutcomesR01HD057956 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2008 to 2012
$2.8M
Mentorship of early-career pediatricians in quantitiative methods and therapeuticK24HD058735 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2009 to 2018
$1.5M
Institutional Training Grant in Pediatric Infectious DiseaseT32HD060558 · NICHD · DUKE UNIVERSITY · PI CUNNINGHAM, COLEEN K. · 2011 to 2015
$1.0M
NCATS NIH HHS UL1 TR001117NCATS NIH HHS UL1TR001117NICHD NIH HHS 1K24HD058735-05NICHD NIH HHS 1R01HD057956-05NICHD NIH HHS 5T32HD060558-03NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS K24 HD058735NICHD NIH HHS R01 HD057956NICHD NIH HHS T32 HD060558
6 · The paper itself

Abstract

purpose of reviewInvasive candidiasis is a serious infection in hospitalized infants that results in significant mortality and morbidity. Fluconazole is approved by the US Food and Drug Administration for prophylaxis of invasive candidiasis in patients undergoing bone marrow transplantation but is not approved for use in infants. This review will describe the history of fluconazole use for prophylaxis in infants. RECENT

findingsLimiting fluconazole prophylaxis to infants with risk factors, in addition to low birth weight and early gestational age, reduces the number of infants treated with fluconazole and the duration of fluconazole therapy for each infant. SUMMARY: Fluconazole prophylaxis appears to be well tolerated for use in premature infants. Reduction in the incidence of invasive candidiasis is observed even when prophylaxis is limited to infants with multiple risk factors. Centers with a low incidence of invasive candidiasis may not benefit from fluconazole prophylaxis. Significant short-term and long-term toxicity and increases in fluconazole-resistant organisms have not been observed with fluconazole use in the intensive care nursery.

Indexed as

Antibiotic ProphylaxisIntensive Care Units, NeonatalAntifungal AgentsCandida albicansCandidiasis, InvasiveDrug Administration ScheduleFemaleFluconazoleHumansIncidenceInfantInfant, NewbornInfant, PrematureInfant, Very Low Birth WeightMalePractice Guidelines as TopicAntifungal AgentsFluconazole

Identifiers

PMID24626156
PMCPMC4042246
OpenAlexW2321050930

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.